← Leaderboards
Hans Joerg Moebius
Athira Pharma, Inc.
$6,312,103
Attributed
$15,227,987
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.8M · FY2020–22$10M$7.5M$5M$2.5M$0
'20
'21
'22
Funding mix
By agency
NIH$15,227,987 · 1
By mechanism
R01$15,227,987 · 1
Top collaborators
- Charles Bernick3 shared
- Xue Hua1 shared
Most similar at Athira Pharma, Inc.
Same institution · by research overlap
- Charles Bernick$8,851,205
- Xue Hua$2,603,781
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposAgingCell PhysiologyAmyloid Beta-42Animal ModelAnimalsApp-Ps1BaseBehaviorBiological MarkersBrainCanis FamiliarisCaregiver BurdenCell InjuryAgedClinical CandidateClinical DevelopmentClinical EfficacyCognitionCognitiveCommunitiesCooperative StudyDementiaAcute
Grant awards (3)
A randomized, placebo-controlled, double-blind study to evaluate safety and efficacy of NDX-1017 treatment in Alzheimer's dementia patients$2,926,978
R01 · FY2022 · AG · contact PI
A randomized, placebo-controlled, double-blind study to evaluate safety and efficacy of NDX-1017 treatment in Alzheimer's dementia patients$4,489,665
R01 · FY2021 · AG · contact PI
A randomized, placebo-controlled, double-blind study to evaluate safety and efficacy of NDX-1017 treatment in Alzheimer's dementia patients$7,811,344
R01 · FY2020 · AG